ASP1517 Phase 3 Clinical Trial - A Multi-center, Randomized, 2-arm, Open-label Study of Intermittent Oral Dosing of ASP1517 in ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 06 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Apr 2017 Planned End Date changed from 1 Sep 2017 to 31 Mar 2018.
- 13 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 31 Mar 2018.